Tezepelumab in patients with allergic and eosinophilic asthma
Allergy · 2024-05 · 79 (5) · 1134-1145
DOI: 10.1111/all.15986 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 26.12.2023. Verfasst von Marco Caminati und 11 weiteren Autor:innen. Beteiligte Einrichtung: Asthma Center and Allergy Unit, Verona Integrated University Hospital & Department of Medicine, University of Verona, Verona, Italy. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca, Amgen.
Abstract (Originalsprache)
Asthma is a heterogeneous disease commonly driven by allergic and/or eosinophilic inflammation, both of which may be present in severe disease. Most approved biologics for severe asthma are indicated for specific phenotypes and target individual downstream type 2 components of the inflammatory cascade. Tezepelumab, a human monoclonal antibody (immunoglobulin G2λ), binds specifically to thymic stromal lymphopoietin (TSLP), an epithelial cytokine that initiates and sustains allergic and eosinophilic inflammation in asthma. By blocking TSLP, tezepelumab has demonstrated efficacy across known asthma phenotypes and acts upstream of all current clinically used biomarkers. In a pooled analysis of the phase 2b PATHWAY (NCT02054130) and phase 3 NAVIGATOR (NCT03347279) studies, compared with placebo, tezepelumab reduced the annualized asthma exacerbation rate over 52 weeks by 62% (95% confidence interval [CI]: 53, 70) in patients with perennial aeroallergen sensitization (allergic asthma); by 71% (95% CI: 62, 78) in patients with a baseline blood eosinophil count ≥300 cells/μL; and by 71% (95% CI: 59, 79) in patients with allergic asthma and a baseline blood eosinophil count ≥300 cells/μL. This review examines the efficacy and mode of action of tezepelumab in patients with allergic asthma, eosinophilic asthma and coexisting allergic and eosinophilic phenotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Asthma Center and Allergy Unit, Verona Integrated University Hospital & Department of Medicine, University of Verona, Verona, Italy.
- Pulmonary Department, Mainz University Hospital, Mainz, Germany.
- David Geffen School of Medicine, University of California, Los Angeles, California, USA.
- Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Department of Medicine, Western University, London, Ontario, Canada.
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Marco Caminati, Marek Lommatzsch, Andrea Matucci, Ian D Pavord
Förderung
- AstraZeneca
- Amgen
Zitieren
APA
Caminati, M., Buhl, R., Corren, J., Hanania, N. A., Kim, H., Korn, S., Lommatzsch, M., Martin, N., Matucci, A., Nasser, S. M., Pavord, I. D., & Domingo, C. (2024). Tezepelumab in patients with allergic and eosinophilic asthma. Allergy, 79(5), 1134-1145. https://doi.org/10.1111/all.15986
Vancouver
Caminati M, Buhl R, Corren J, Hanania NA, Kim H, Korn S, et al. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024;79(5):1134-1145. doi:10.1111/all.15986
BibTeX
@article{Caminati2024,
author = {Caminati, Marco and Buhl, Roland and Corren, Jonathan and Hanania, Nicola A and Kim, Harold and Korn, Stephanie and Lommatzsch, Marek and Martin, Neil and Matucci, Andrea and Nasser, Shuaib M and Pavord, Ian D and Domingo, Christian},
title = {Tezepelumab in patients with allergic and eosinophilic asthma},
journal = {Allergy},
year = {2024},
volume = {79},
number = {5},
pages = {1134--1145},
doi = {10.1111/all.15986}
}
EUVIMED